# Investment memo referral confidentiality: a guide | SourceX

Canonical: https://refer.sourcex.si/guides/how-to-keep-investment-memos-out-of-referral-workflows
Last updated: 2026-11-05

Treat the memo as a closed document. Nothing in it travels into a referral note, an introduction email, a tracker field, a portal submission or a conversation with SourceX. A memo blends diligence received under confidentiality terms, board and information-rights material and the fund's own judgments, and a referral needs none of it. Rebuild the few facts an introduction uses from what the company's CEO says for that purpose and SourceX's published criteria, and let the CEO decide what the company tells SourceX. Fund counsel decides what the fund's agreements allow.

This page is for the general counsel, compliance lead or platform lead at a venture fund that takes part in SourceX's referral program. A sibling guide keeps the flow running the other way, so that a possible reward never shapes [investment selection or the memo itself](/guides/how-to-keep-referral-rewards-out-of-investment-selection). Matter material covered by privilege has [its own checklist](/guides/how-to-keep-privileged-material-out-of-data-referral-discussions), and a sale's data room is a separate case again. The question here is the memo: the single document where everything a fund knows about a company ends up, and the one most likely to be pasted into a referral.

## What an investment memo holds, and why none of it belongs in a referral

A memo is a composite. Its paragraphs come from at least five places, each with its own terms:

- **Diligence material from the company,** usually received under a confidentiality agreement. NVCA's model life-science confidential disclosure agreement, in the copy posted on its site, limits the receiving investor's use of the information to internal review of the proposed deal or business relationship (our paraphrase of a search excerpt). NVCA's model documents page lists a version updated in July 2025, so read the current form and, above all, the agreement your fund actually signed.
- **Board and information-rights material.** SourceX's screening page says that what a fund knows about a company's systems usually arrived through board packs or information rights, that this knowledge comes with a duty, and that it is "a reason to ask the CEO, never material to pass along."
- **Third parties' information:** expert calls, customer references, co-investors' notes.
- **Facts about other companies:** customers, suppliers and competitors named in a market map.
- **The fund's own judgments:** thesis, valuation, risks, views on management.

A referral is an ask to one CEO, and none of those five sources is the CEO speaking for that purpose. That is the whole case for the wall.

The program points the same way. Section 4.2 of the sample Channel Partner Agreement says: "This Agreement gives Partner no authority to share a supplier's inventory, records, raw data or personal information, or to access extraction systems." Section 4.4 adds: "Partner must not collect or retain supplier dataset copies through the referral program without separate written authorization." No partner collects company data for SourceX, and none forwards a company's files. SourceX's own process starts with the company, in SourceX's words: the first step is "A few questions, no files," and "no records are shared at this stage." Its trust page puts scope in the company's hands: "The supplier decides which systems, records and date ranges are in scope. Everything else stays out."

## The purpose of a referral, and who may see what

The purpose is narrow: ask one CEO whether they want a conversation with SourceX and, if they do, make the introduction. Permission for that introduction is not permission to move any dataset, and it is not permission for a public story. The information-flow map follows from the purpose.

| Recipient | May receive | Never receives |
|---|---|---|
| The company's CEO | SourceX's own description, a link to the published criteria, your interest, and the option to apply without you | Anything from the memo, including your view of the company's records |
| SourceX | The company's name, the CEO's name and contact, the CEO's agreement and its date | Memo facts, figures, attachments or opinions |
| The fund's referral log | Dated events: asked, agreed, declined, introduced, withdrawn | Memo links, excerpts or deal-team notes |
| The deal team | Nothing from the referral | Not applicable: this lane never feeds the memo |
| Other colleagues | Only what the log's access rules allow | Memo content routed through the referral |

## The source-separation operating guide

Each memo section, the referral steps it must never reach, and what replaces it when an introduction needs a fact at all.

| Memo section | Typical content | Must never reach | What replaces it |
|---|---|---|---|
| 1. Company overview | Headcount, founding year, locations | Introduction note, tracker fields, portal submission | The CEO's answer given for this purpose, or a dated public fact |
| 2. Product, customers, contracts | Customer names, contract terms | Every referral step | Nothing; rights questions go from the company to SourceX |
| 3. Financials and metrics | Revenue, burn, unit economics | Every referral step | Nothing; no referral needs a financial fact |
| 4. Technical and data diligence | Systems, data volumes, IT findings | Introduction note, portal submission, any SourceX conversation | The CEO's own description of systems and years of records |
| 5. Legal and IP review | Counsel's findings, disputes | Every referral step | Nothing; the company's counsel deals with rights |
| 6. Management and references | Views on people, reference calls | Every referral step | Nothing |
| 7. Thesis, valuation, risks | The fund's judgments | Every referral step | Nothing |
| 8. Market map | Customers, suppliers and competitors by name | Any referral of those other companies | Nothing; those relationships belong to someone else |
| 9. Appendices and exports | Data-room files, spreadsheets, decks | Every referral step and every referral tool | Nothing |

Six of nine rows have no replacement, because a referral works without them. For the rows that do, the replacement is a conversation, not a document. SourceX's screening page lists the questions to put through the relationship holder, "never from files, samples or logins": peak full-time headcount and when it peaked, contractors excluded; when the company's own records start and in which systems; who created the records and whether any belong to clients; where the company is and what language its records are in; and whether the CEO knows about the idea and wants the conversation.

**Method note.** The nine sections are a generic outline of a venture investment memo written for this guide; funds structure memos differently, and no fund's memos were reviewed. Recipients and replacements apply SourceX's terms (version 2026-10-22.2, since replaced by version 2026-11-04), its who-qualifies, trust and process pages and sections 4.2 and 4.4 of the sample agreement, read on 2026-10-28, with NVCA's model confidential disclosure agreement as paraphrased above. Nothing here measures how often memo content reaches referral tools; no such data has been published.

## What the CEO's decision needs, and what it can do without

The next decision belongs to the CEO: talk to SourceX or not. That decision needs five things, and the memo supplies none of them: what SourceX does, in its own words; the published criteria, linked; that the CEO decides; your interest, with the fact that the company's payment is unchanged because section 4 of the terms has SourceX pay any reward separately; and the option to apply directly.

An Illustrative three-sentence note: "SourceX licenses business records from companies for AI training; its published criteria are at the link below, and whether to look further is entirely your call. If you'd like an introduction I can make one, and SourceX may pay me a reward if a deal completes, which never comes out of what your company is paid. You can also apply to SourceX yourself without me."

Notice what the note leaves out. A sentence like "your 14 years of ticket history looks like a fit" tells the CEO that the fund's memo has been read for a purpose the CEO never agreed to. Even when accurate, it is the wrong source.

## Where memos leak into referral tools, and the control for each

- **Trackers and CRMs.** Keep referral records in their own pipeline with no field that links to a memo, no attachment slot and automatic association with deal records switched off. The [shadow data room review](/guides/how-to-avoid-building-a-shadow-data-room-in-your-crm) shows how logged email and call notes file attachments without anyone choosing to.
- **AI assistants.** An assistant asked "what do we know about this company?" will happily blend memo, board notes and referral log. Keep the memo workspace and the referral workspace out of each other's scope; [the MCP guide for committee memos](/resources/mcp/mcp-investment-committee-memo) describes how memo tooling traces sources, which is the reason to keep that tooling away from referral work.
- **Email.** Start the introduction in a new thread. A forwarded memo thread carries its history with it.
- **Templates.** Remove any "background" or "why this company" field from the introduction template. Empty fields invite memo text.
- **People.** The person who read the memo can still write the note if every line comes from the CEO and SourceX's pages. Counsel may prefer someone who never read it.

## Escalation, withdrawal and publication: three separate decisions

**Escalation.** When anyone proposes using a memo fact in a referral, the work stops and fund counsel decides. Make "no" the default answer, and record the decision either way.

**Withdrawal.** If the CEO declines, or agrees and later withdraws, log the date and stop. The answer never travels back into the memo or into any investment discussion, and nothing is said to SourceX beyond what the CEO wants said.

**Publication.** Agreeing to an introduction does not license a case study, an LP letter paragraph or a conference anecdote. SourceX's process page says of licensing deals that "Neither side publicizes the deal," and the company's CEO decides whether its name appears anywhere at all. Keep referral and memo content out of fund marketing; the [two-activity boundary](/guides/separate-a-company-referral-from-an-investment-introduction) covers the line between referral work and any investment conversation about SourceX.

## Two memos, two referrals (Illustrative)

Illustrative. Both companies are generic, their facts invented, and neither ending is a real result.

**A portfolio company.** A 2023 memo on a claims software company records 260 employees and 14 years of support tickets in one system. Two years later the platform lead thinks SourceX might interest the CEO. The note goes out without a single memo fact. The CEO replies that headcount peaked at 240 and usable history runs 11 years, and wants the introduction. The referral log records the CEO's figures and the date; the memo is never opened. Whoever submits has already signed the Channel Partner Agreement, as section 1 of the terms requires.

**A passed deal.** The fund passed on a 400-person claims processor after diligence under a confidentiality agreement. An associate proposes an introduction, citing the systems inventory from the data room. Counsel rules that the diligence material stays under that agreement and is not used. A partner who knows the CEO independently may mention SourceX in general terms, pointing only to the published criteria, or the fund may leave the company alone; counsel and the partner decide which, and the associate's proposal is logged as declined.

## Where this guide can be wrong

- **Your agreements decide, not this page.** Counsel may read the fund's confidentiality agreements, side letters and policies as stricter or looser than this guide assumes. Their reading governs.
- **Memory has no wall.** People who read memos keep what they read. The controls govern what is written and sent; they cannot erase knowledge, which is why the source rule matters more than the tooling.
- **Small teams cannot separate people.** Where two partners do everything, rely on the written source rule and counsel's view.
- **CEOs volunteer detail.** A CEO may share more than an introduction needs. Use what serves the introduction, and pass nothing to SourceX that the CEO has not chosen to tell it.
- **Untested.** No published data shows how often memo content leaks into referral work, or how well these controls prevent it. Count escalations and their outcomes each quarter.

## Next step

> **Refer a company. No cap on rewards.** Default reward on a company's first qualifying transaction: the greater of $50,000 plus 5% and 15% of Actual Supplier Payout, with no cap; further qualifying transactions first agreed within 12 months of the first Closing pay 15%. Eligibility and payment conditions apply, including the USD 100,000 Minimum Transaction, and a signed Schedule A or addendum can differ. A lead, meeting or signature alone does not trigger payment.

With the memo walled off and the note rebuilt from the CEO's own words, [register for a partner link](/register), point the CEO to [who qualifies](/who-qualifies) so the company screens itself, and keep the [program terms](/terms) open beside your referral log.

Keeping memos out of referral work is a fund operations question; deciding whether SourceX is worth an investment is a different one, and anyone with that second question can ask for investor materials through the [SourceX investor overview](https://sourcex.si/investors).

This article is for information only and is not an offer to sell or a solicitation of an offer to buy securities. Any offering by SourceX is made only to verified accredited investors through its offering documents.

## Sources

- https://refer.sourcex.si/terms
- https://sourcex.si/documents/partner/SourceX_Channel_Partner_Agreement_Sample.pdf
- https://sourcex.si/trust
- https://sourcex.si/how-it-works
- https://refer.sourcex.si/who-qualifies
- https://nvca.org/wp-content/uploads/2019/06/NVCA-Model-Document-Life-Science-Confidential-Disclosure-Agreement.doc
- https://nvca.org/model-legal-documents/
- https://sourcex.si/investors
